Hepatitis B RNA and Core-Related Antigen Provide Value Beyond DNA in Evaluating e But Not Surface Antigen Clearance
Copyright © 2023 AGA Institute. All rights reserved..
In chronic hepatitis B virus (HBV) infection, hepatitis B e antigen (HBeAg) and hepatitis B surface antigen (HBsAg) clearance are important milestones toward immune control.1 A drop in HBV DNA is an established correlate of both HBeAg and HBsAg clearance.2 We evaluated changes in HBV RNA and hepatitis B core-related antigen (HBcrAg) levels, markers of transcriptional activity of covalently closed circular DNA (cccDNA),3,4 with HBeAg and HBsAg clearance, and compared them with changes in HBV DNA level among adult participants in the Hepatitis B Research Network (HBRN).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association - 21(2023), 7 vom: 05. Juli, Seite 1957-1959 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
King, Wendy C [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
63231-63-0 |
|---|
| Anmerkungen: |
Date Completed 26.06.2023 Date Revised 01.07.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.cgh.2022.06.019 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM343706067 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM343706067 | ||
| 003 | DE-627 | ||
| 005 | 20231226021056.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cgh.2022.06.019 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1145.xml |
| 035 | |a (DE-627)NLM343706067 | ||
| 035 | |a (NLM)35850413 | ||
| 035 | |a (PII)S1542-3565(22)00660-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a King, Wendy C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hepatitis B RNA and Core-Related Antigen Provide Value Beyond DNA in Evaluating e But Not Surface Antigen Clearance |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.06.2023 | ||
| 500 | |a Date Revised 01.07.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 AGA Institute. All rights reserved. | ||
| 520 | |a In chronic hepatitis B virus (HBV) infection, hepatitis B e antigen (HBeAg) and hepatitis B surface antigen (HBsAg) clearance are important milestones toward immune control.1 A drop in HBV DNA is an established correlate of both HBeAg and HBsAg clearance.2 We evaluated changes in HBV RNA and hepatitis B core-related antigen (HBcrAg) levels, markers of transcriptional activity of covalently closed circular DNA (cccDNA),3,4 with HBeAg and HBsAg clearance, and compared them with changes in HBV DNA level among adult participants in the Hepatitis B Research Network (HBRN) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Hepatitis B Surface Antigens |2 NLM | |
| 650 | 7 | |a Hepatitis B e Antigens |2 NLM | |
| 650 | 7 | |a DNA, Viral |2 NLM | |
| 650 | 7 | |a Antigens, Surface |2 NLM | |
| 650 | 7 | |a RNA |2 NLM | |
| 650 | 7 | |a 63231-63-0 |2 NLM | |
| 650 | 7 | |a Hepatitis B Core Antigens |2 NLM | |
| 650 | 7 | |a DNA, Circular |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Sterling, Richard K |e verfasserin |4 aut | |
| 700 | 1 | |a Hinerman, Amanda S |e verfasserin |4 aut | |
| 700 | 1 | |a Lok, Anna S F |e verfasserin |4 aut | |
| 700 | 1 | |a Cloherty, Gavin A |e verfasserin |4 aut | |
| 700 | 1 | |a Ghany, Marc G |e verfasserin |4 aut | |
| 700 | 0 | |a HBRN HBV NOVELASSAYS GROUP |e verfasserin |4 aut | |
| 700 | 1 | |a Wahed, Abdus S |e investigator |4 oth | |
| 700 | 1 | |a Chung, Raymond T |e investigator |4 oth | |
| 700 | 1 | |a Janssen, Harry L A |e investigator |4 oth | |
| 700 | 1 | |a Khalili, Mandana |e investigator |4 oth | |
| 700 | 1 | |a Lau, Daryl T Y |e investigator |4 oth | |
| 700 | 1 | |a Lee, William M |e investigator |4 oth | |
| 700 | 1 | |a Lisker-Melman, Mauricio |e investigator |4 oth | |
| 700 | 1 | |a Terrault, Norah |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association |d 2003 |g 21(2023), 7 vom: 05. Juli, Seite 1957-1959 |w (DE-627)NLM147178851 |x 1542-7714 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2023 |g number:7 |g day:05 |g month:07 |g pages:1957-1959 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cgh.2022.06.019 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2023 |e 7 |b 05 |c 07 |h 1957-1959 | ||